OncoMatch/Clinical Trials/NCT06371586

Neo-Sequence 2：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC

Is NCT06371586 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy for gastric cancer.

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06371586Data as of May 2026

Treatment: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy — The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Disease stage

Required: Stage T3-4NANYM0 (AJCC 8th edition)

T3-4NanyM0 gastric cancer or gastroesophageal junction cancer (refer to AJCC staging, 8th edition)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

Neutrophils >1.5G/L, Hb >90g/L, PLT >100G/L

Kidney function

Cr <1.0ULN

Liver function

ALT and AST <2.5ULN; TBIL <1.5 ULN

Cardiac function

Left ventricular ejection fraction >60%

Neutrophils>1.5G/L, Hb>90g/L, PLT>100G/L; ALT and AST<2.5ULN; TBIL<1.5 ULN; Cr<1.0ULN; Left ventricular ejection fraction>60%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify